Technical Description
This technology is a novel steroidal alkaloid-based drug, veratramine, designed to inhibit LdDPCK enzyme in Leishmania donovani for therapeutic application.
Problems Addressed
- Limited Drug Efficacy
- Limited Treatment Accessibility
- Severe Side Effects
- Unresponsive Parasite Strains
- Reduced Immunotherapy Success
- Limited Leishmanicidal Activity
- High Treatment Costs
Tech Features
- Efficient Steroidal Composition
- Enhanced Anti-Leishmanial Activity
- Targeted Kinase Inhibition
- Potent Drug Molecule
- Optimized Parasite Management
- Advanced Resistance Control
Target Audience
- Pharmaceutical Industry
- Biotechnology Sector
- Healthcare Industry
- Academic & Research Institutions
- Therapeutics & Prevention Sector
Tech ID: P27-1382 TRL 4 Patent Status: Published Available For Exclusive and Non-exclusive License
